BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:PharmaEssentia Corporation readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies PharmaEssentia Corporation's drug
 s run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06468033-9910@assetmemo.bio
DTSTAMP:20261121T005948Z
DTSTART;VALUE=DATE:20271118
DTEND;VALUE=DATE:20271119
SUMMARY:Ropeginterferon alfa-2b (Besremi): Phase 3 readout est. (NCT0646803
 3)
DESCRIPTION:Ropeginterferon alfa-2b (Besremi)\, phase 3\, Myelofibrosis.\nS
 tudy: P1101 in Treating Patients With Early PMF or Overt PMF at Low or Int
 ermediate-1 Risk\nEstimated primary completion: 18 November 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/ropeginterferon-alfa-2b-besre
 mi#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6468033
URL:https://assetmemo.bio/drug/ropeginterferon-alfa-2b-besremi#upcoming-eve
 nts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06514807-9910@assetmemo.bio
DTSTAMP:20261121T005948Z
DTSTART;VALUE=DATE:20280315
DTEND;VALUE=DATE:20280316
SUMMARY:Ropeginterferon alfa-2b (Besremi): Phase 3 readout est. (NCT0651480
 7)
DESCRIPTION:Ropeginterferon alfa-2b (Besremi)\, phase 3.\nStudy: A Study to
  Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential 
 Thrombocythaemia Patients\nEstimated primary completion: 15 March 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/ropeginterferon-alfa-2b
 -besremi#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06514807
URL:https://assetmemo.bio/drug/ropeginterferon-alfa-2b-besremi#upcoming-eve
 nts
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
